Epilepsy: pitolisant’s promising early Phase II study confirms the interest of SynapCell’s approach to AED discovery
Grenoble | APRIL 24TH, 2014

The recent clinical data obtained with a new antiepileptic drug (AED) candidate called pitolisant, developed by Bioprojet, in an early Phase II study [1] confirms the interest in SynapCell’s strategic approach, associating animal models and EEG, as a translational marker of brain’s function. Moreover, it validates the relevance of our animal models for drug discovery in Epilepsy, GAERS and MTLE mouse.

[1] Efficacy of the histamine 3 receptor (H3R) antagonist pitolisant (formerly known as tiprolisant; BF2.649) in epilepsy: dose-dependent effects in the human photosensitivity model Kasteleijn-Nolst Trenité D. et al. Epilepsy Behav, 2013